KOD News and Press, Kodiak Sciences Inc From 10/14/19

This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. Winning Bounc...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

PALO ALTO, Calif. , Oct. 11, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced promising safety, efficacy and durability data from its o...

Noteworthy events during the week of October 13 - 19 for healthcare investors. More news on: Flexion Therapeutics, Inc., Johnson & Johnson, ArQule, Inc., Healthcare stocks news, , Read more ...

PALO ALTO, Calif. , Oct. 11, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) will host an R&D Day in San Francisco to highlight significant progress in the development of its lead therapeutic candidate KSI-301. The R&D event, including a live video stream, will be held o...

PALO ALTO, Calif. , Oct. 10, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced that the first patients have been treated in the DAZZLE pivotal...

It's almost time for the American Academy of Opthalmology's (AAO) annual meeting again, and this year's event will contain some high-stakes presentations. This year, all three of these biopharmaceutical companies will present clinical trial results that could send their stock prices soaring -- o...

PALO ALTO, Calif. , Oct. 7, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that Charles C. Wykoff , M.D., Ph.D., will present first-...

Over the past three months, the Nasdaq Biotechnology index has tumbled around 9.5% and industrywide worries have pressured share prices of some companies that didn't deserve a market beatdown. Axsome Therapeutics (NASDAQ: AXSM) , BridgeBio Pharma (NASDAQ: BBIO) , and Kodiak Sciences (...